About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

ph
No mention of ERX in there

02:47ihavenoclueRE: Riskypete ... ERXBuy
You say the interview says there will be lots of good news soon. ..Mon 18:32sharedealershare price?Strong Buy
well according to some on this site E.I.R.X. are about to make an announcement in the near future as regards to future progress of the company & affiliates, this should be very positive news, in that e.i.r.x. are at the fore-front of apoposis research & development, and have already patented certain parts of their re-search that protect intellectual rights e.t.c.
they are already in colaboration with a number of companies including meryk. and have taken on board Auvation from scotland who where in the same line of business and who,s aquisition was a perfect fit according to E.I.R.X. not to mention the french company (who,s name eludes me at the moment) this company has the ability to manafacture, as well as assist in research under licence to e.i.r.x.
I would be suprised if e.i.r.x. had no imput into last weeks announcements regarding the new sucsessful approach to treating cancers, via the apoptosis route, as they are years ahead of most in this field, and possibly all, so when an announcement is made don,t be suprised by a massive surge in the share price, as the big drug companies move in an attempt to buy in, or even buy them out, as they have most to loose if an absolute cure for cancers becomes a reallity, i.e. drugs that at most control cancer will be confined to history as will their profits.
What happened last week is just the beginning of a new era in medical science, so fill you,r boots with shares of e.i.r.x. I have.

Sharedealer100.

the press is wrtting a lot on apoptosis - at the end of the day.. they are all using ERX methods.. so therefore, we are bound to get something. and rather big I would say, after what J Pool said in his interview.. he said very soon and that was back in June, the way the SP has been going it does look soon.. look at all the news out below, its all available on google news, just search Apoptosis


Scientists Identify Compounds That Stimulate Stem Cell Growth In ...
Haber Sağlık, Turkey - 5 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...

Harvard scientists report key stem cell research findings
Pharmaceutical Business Review - 9 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...

Malignant glioma: engineered adenovirus induces cells to die by ...
Xagena.it, Italy - 14 hours ago
... The cells showed no sign of having been killed by apoptosis. ... Many cancer therapies focus on restoring or enhancing apoptosis to combat the disease. ...

EIRX THERAPEUTICS PLC ORD 0.2P Share Price direct to your mobile ...
Life Style Extra, UK - 17 hours ago
... I would be suprised if eirx had no imput into last weeks announcements regarding the new sucsessful approach to treating cancers, via the apoptosis route, as ...

LB-18, derived from a marine sponge, induces apoptosis in ...
Therapeutics Daily (subscription) (press release), PA - 17 hours ago
... 4 - (NewsRx.com) -- Scientists have isolated a novel synthetic drug, LB-18, from a marine sponge that can induce caspase-independent apoptosis in neuroblastoma ...

Harvard Scientists Report Key Stem Cell Research Findings
International News Service, Australia - 18 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...

Breakthrough In The Identity Of Compounds That Encourage Stem Cell ...
MedIndia, India - 18 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...

Carbon Monoxide May Prevent Pre-Eclampsia
MedIndia, India - 19 hours ago
... is used, according to Bainbridge et al., who have published a paper called "Carbon monoxide inhibits hypoxia/reoxygenation-induced apoptosis and secondary ...

New hope for patients with lung and joint disease
News-Medical.net, Australia - 23 hours ago
... These drugs trigger a process of cell 'suicide' called apoptosis in which the inflammatory cells, called neutrophils, destroy themselves before being removed ...

Scientists identifiy key compounds that stimulate stem cell growth ...
News-Medical.net, Australia - 4 Sep 2006
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...

patents ERX have a applied for

http://v3.espacenet.com/results?IA=eirx&sf=q&CY=gb&LG=en&DB=EPODOC&st=IA&kw=eirx&Submit=SEARCH&=&=&=&=&=&PGS=10&FIRST=1

Apoptosis!!! ;-)

RESULT LIST
17 results found in the Worldwide database for:
eirx (applicant or inventor)
(Results are sorted by date of upload in database)



1 SCREENING-VERFAHREN in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE)
EC: G01N33/50D2; G01N33/543K IPC: G01N33/50; G01N33/543; G01N33/50 (+2)
Publication info: AT325889T - 2006-06-15

2 Enzymes involved in apoptosis in my patents list
Inventor: MURPHY FINBARR J (IE); SHEEHAN DYAN E (IE); (+3) Applicant: EIRX THERAPEUTICS LTD
EC: C07K14/47A33 IPC: A61K48/00; A61K38/54; C07K14/47 (+11)
Publication info: US2006121498 - 2006-06-08

3 SCREENING METHOD in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE)
EC: G01N33/50D2; G01N33/543K IPC: C12Q1/00; G01N33/50; G01N33/543 (+3)
Publication info: DE60119524D - 2006-06-14

4 Human delta-n p73 molecules and uses thereof in my patents list
Inventor: HAYES IAN; LAURENZI VINCENZO DE; (+6) Applicant: EIRX THERAPEUTICS LTD
EC: C07K14/47A1 IPC: C07K14/47; C12N15/12; A61K38/00 (+7)
Publication info: AU2002327945 - 2003-04-01

5 ELAVL-1 in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (US)
EC: C07K14/47A33 IPC: C07K14/47; C07K14/435; (IPC1-7): C12Q1/68 (+2)
Publication info: US2005042643 - 2005-02-24

6 Apoptosis-related kinase/GPCRs in my patents list
Inventor: SEERY LIAM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTICS LTD (US)
EC: G01N33/50D2; G01N33/50D2B; (+1) IPC: G01N33/50; G01N33/574; G01N33/50 (+3)
Publication info: US2005019746 - 2005-01-27

7 Apoptosis-related kinase/GPCRs in my patents list
Inventor: SEERY LIAM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTICS LTD (US)
EC: G01N33/50D2; G01N33/50D2B; (+1) IPC: G01N33/50; G01N33/574; G01N33/50 (+2)
Publication info: US2004219616 - 2004-11-04

8 KINASES AND GPCRS INVOLVED IN APOPTOSIS in my patents list
Inventor: SEERY LIAM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTICS LTD (IE); SEERY LIAM (IE); (+2)
EC: G01N33/50D2; G01N33/50D2B; (+1) IPC: G01N33/50; G01N33/574; G01N33/50 (+2)
Publication info: WO2004065959 - 2004-08-05

9 SURVIVIN in my patents list
Inventor: HAYES IAN (IE); COTTER TOM (IE); (+5) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+6)
EC: C07K14/47A1A; C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03091384 - 2003-11-06

10 EARLY STAGE REDOX-RELATED APOPTOSIS MODULATOR-2 (ESRAM-2) in my patents list
Inventor: HAYES IAN (IE); COTTER THOMAS (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+3)
EC: C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03054010 - 2003-07-03


11 TGNP in my patents list
Inventor: HAYES IAN (IE); COTTER THOMAS (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+3)
EC: C07K14/47A33; C12Q1/68M6; (+1) IPC: C07K14/47; C12Q1/68; G01N33/50 (+8)
Publication info: WO03050302 - 2003-06-19

12 P55PIK in my patents list
Inventor: HAYES IAN (IE); COTTER THOMAS (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+3)
EC: C07K14/47A33; C12N9/12B1B; (+2) IPC: C07K14/47; C12N9/12; C12Q1/68 (+12)
Publication info: WO03048361 - 2003-06-12

13 APOPTOSIS in my patents list
Inventor: HAYES IAN (IE); KROEMER GUIDO (FR); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); INST GUSTAVE ROUSSY L (FR); (+5)
EC: A61K38/46; C12Q1/48B; (+1) IPC: A61K38/46; C12Q1/48; G01N33/68 (+5)
Publication info: WO03027671 - 2003-04-03

14 MODEL SYSTEM in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTIC LTD (IE); COTTER TOM (IE); (+2)
EC: C12N15/10C; C12Q1/68P IPC: C12N15/10; C12Q1/68; C12N15/10 (+2)
Publication info: WO0231189 - 2002-04-18

15 SCREENING METHOD 2 in my patents list
Inventor: COTTER TOM (IE); DALY PETER (IE); (+3) Applicant: EIRX THERAPEUTICS LTD (IE); COTTER TOM (IE); (+4)
EC: G01N33/50D2 IPC: G01N33/50; G01N33/50; (IPC1-7): C12Q1/68 (+1)
Publication info: WO0220834 - 2002-03-14

16 Screening method 2 in my patents list
Inventor: COTTER TOM; DALY PETER; (+3) Applicant: EIRX THERAPEUTICS LTD
EC: IPC: C12Q1/68; G01N33/50; C12Q1/68 (+3)
Publication info: AU8426401 - 2002-03-22

17 SCREENING METHOD in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE) Applicant: EIRX THERAPEUTICS LTD (IE); COTTER TOM (IE); (+1)
EC: C12Q1/68A6 IPC: C12Q1/68; C12Q1/68; (IPC1-7): C12Q1/68
Publication info: WO0146468

RTTNews) - Gentium S.p.A. (GENT | charts | news | PowerRating) on Tuesday said it would make an oral presentation entitled, "Defibrotide Modulates Immune Functions Of Endothelial Cells - Impact For Transplantation And Cancer Therapy," to show evidence that Defibrotide can protect endothelial cells from conditioning-mediated apoptosis, which suggests that the drug may be used as a prophylactic in patients at risk for endothelial complications. The results will be presented by Gunther Eissner at the 16th European Congress of Immunology on September 7, 2006 in Paris, France.

According to the company, the evidence demonstrates that Defibrotide has anti-inflammatory activity because it prevents transendothelial migration of immune effector cells, and it can reduce the chemotherapy-induced antigenicity of endothelial cells towards allogeneic cytotoxic T lymphocytes. In addition to these endothelium stabilizing functions, recent pre-clinical evidence suggested that Defibrotide has anti-neoplastic properties, which may be due to its ability to prevent tumor angiogenesis. The results demonstrated that Defibrotide reduces blood vessel formation, when administered on a daily basis and also it reduced tumor angiogenesis in the murine dorsal skin fold chamber after inoculation of cells from the human gastric cancer TMK.

ph

Where did you get this info from ?

http://v3.espacenet.com/results?IA=eirx&sf=q&CY=gb&LG=en&DB=EPODOC&st=IA&kw=eirx&Submit=SEARCH&=&=&=&=&=&PGS=10&FIRST=1

http://v3.espacenet.com/results?IA=eirx&sf=q&CY=gb&LG=en&DB=EPODOC&st=IA&kw=eirx&Submit=SEARCH&=&=&=&=&=&PGS=10&FIRST=1

sorry

http://v3.espacenet.com/results?IA=eirx&sf=q&CY=gb&LG=en&DB=EPODOC&st=IA&kw=eirx&Submit=SEARCH&=&=&=&=&=&PGS=10&FIRST=1

ph
thanks will have a read !

there is a lot to read.. but its a darned good read

going to get more at .0017p I hope

PH

I GOT IN AT .24 and was just going to sit and wait as a long term hold,but might buy more if it drops, ??

I know I will, we already know news is around the corner.. its expected this month..

cheeky mm; knocked the price down, they then bought and then whacked the sp right up.. talk about a rip off merchants

Riskypete ... ERXBuy

That's no recommendation, he writes on a bb and uses the same texts as you.

sww

I tend to agree with your first post ! there is a lot of similar research going on .

I don't want to star a fight, but I feel ph is one and the same risky pete.

The bargepole is now in full use.

no.. I am not, I am cannon over at AD fvn .com

Gentium to Present Data Showing Defibrotide Modulates Immune Functions; Endothelial Cell Protection and Anti-angiogenic Activity Has Impact For Transplantation And Cancer Therapy


VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Sept. 5, 2006 - Gentium S.p.A. (NASDAQ:GENT) (the Company) today announced that Gunther Eissner, Ph.D., Department of Hematology, Regensburg University Medical Center, Regensburg, Germany, and Massimo Iacobelli, M.D., Senior Vice President, Scientific Director, Gentium, S.p.A., will make an oral presentation entitled, "Defibrotide Modulates Immune Functions Of Endothelial Cells - Impact For Transplantation And Cancer Therapy," at the 16th European Congress of Immunology. The Congress is being held from September 6-9, 2006 in Paris, France. The presentation will take place on Thursday afternoon, September 7, 2006 in the Immune Interventions Workshop--Immunohematology Track D section in Room 251 at 3:00 p.m. local time.

In their presentation, Drs. Eissner and Iacobelli will show evidence that Defibrotide can protect endothelial cells from conditioning-mediated apoptosis, which suggests that the drug may be used as a prophylactic in patients at risk for endothelial complications. The evidence demonstrates that Defibrotide has anti-inflammatory activity because it prevents transendothelial migration of immune effector cells, and it can reduce the chemotherapy-induced antigenicity of endothelial cells towards allogeneic cytotoxic T lymphocytes.



In addition to these endothelium stabilizing functions, recent pre-clinical evidence suggests that Defibrotide has anti-neoplastic properties, which may be due to its ability to prevent tumor angiogenesis. The anti-angiogenic potential of Defibrotide was tested in vitro using a novel angiogenesis kit (AngioKit(TM)) and in vivo using the dorsal skin fold chamber model in mice. The results demonstrated that Defibrotide at concentrations corresponding to pharmacologic Defibrotide blood levels (100 ug/mL) reduces blood vessel formation significantly (p=0.022), when administered on a daily basis. Furthermore, Defibrotide significantly reduced tumor angiogenesis in the murine dorsal skin fold chamber after inoculation of cells from the human gastric cancer TMK. Regarding the mechanism of action of Defibrotide, initial Western blotting results show that Defibrotide reduces phosphorylation-activation of p70S6 kinase, which is a key target in the PI3K/Akt/mTOR signaling pathway linked to angiogenesis. Additional in vitro data suggest that Defibrotide's action is independent of a blockade of vascular endothelial growth factor (VEGF).

Dr. Laura Ferro, Chairman and Chief Executive Officer of Gentium, commented on the presentation, "The pre-clinical data demonstrate Defibrotide's activity in multiple pathways. Taken together, the data suggest that while Defibrotide is known for its endothelium-protecting function, it also can inhibit blood vessel formation. These data support our clinical strategy to pursue further testing of Defibrotide as an anticancer agent, either as a monotherapy or in combination with other drugs, especially as it appears that it can work synergistically with other VEGF-dependent, anti-angiogenic substances."

About VOD

Veno-occlusive disease (VOD) is a potentially life-threatening condition. Certain high dose chemotherapy and radiation therapies and stem cell transplantation (SCT) can damage cells of the blood vessels and result in VOD, a blockage of the small veins of the liver that can lead to liver failure and the failure of other organs (Severe VOD). SCT is a frequently used treatment following high dose chemotherapy and radiation therapy. The International Bone Marrow Transplant Registry estimated that approximately 45,000 people received blood and bone marrow transplants, which are types of SCT, in 2002. Based on the Company's review of more than 200 published papers, it believes that approximately 20% of patients who undergo SCT develop VOD, approximately one-third of those who develop VOD progress to Severe VOD, and approximately 80% of Severe VOD patients die within 100 days of the SCT. The Company believes that there are no approved therapies to treat or prevent VOD in the U.S. or the EU.

About Gentium

Gentium S.p.A. is a biopharmaceutical company located in Villa Guardia (Como), Italy that is focused on the research, discovery and development of drugs derived from DNA extracted from natural sources, and drugs that are synthetic derivatives, to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate in the U.S., is an investigational drug that has been granted Orphan Drug status by the U.S. FDA to treat Severe VOD and Fast Track designation for the treatment of Severe VOD in recipients of stem cell transplants.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20F filed with the Securities and Exchange Commission under the caption "Risk Factors."